@article{CCO28788,
author = {Niccolo Allievi and Paolo Goffredo and Alan F. Utria and Michele Pisano and Elia Poiasina and Alessandro Lucianetti and Paige Zhou and Imran Hassan},
title = {The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases},
journal = {Chinese Clinical Oncology},
volume = {8},
number = {5},
year = {2019},
keywords = {},
abstract = {Background: Recent evidence suggests that a mutation in the KRAS gene has a significant impact on the clinical behavior and prognosis of patients with metastatic colorectal cancer. The KRAS mutation (m-KRAS) has been associated with decreased survival among patient undergoing treatment with a curative and palliative intent. This is believed to be secondary to a reduced response to anti-EGFR chemotherapy agents and a more intrinsically aggressive biology. The aims of this study were to identify risk factors for m-KRAS in patients with curatively resected colorectal cancer and synchronous liver metastases and to assess its association with disease-specific survival (DSS).
Methods: The Surveillance, Epidemiology and End Results (SEER) Database was surveyed for patients undergoing resection of colorectal cancer and synchronous liver metastases from 2010 to 2015.
Results: A total of 806 patients were included, of which 40% hadm-KRAS. Right-sided primary lesions (OR 2.56, 95% CI: 1.90–3.44, P},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/28788}
}